deltatrials
Terminated PHASE3 INTERVENTIONAL 1-arm NCT03563053

Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study (OLE-IEDAT)

Open-label, Long-term, Extension Treatment Using Intra-Erythrocyte Dexamethasone Sodium Phosphate (EryDex System) in Patients With Ataxia Telangiectasia Who Participated in the ATTeST-IEDAT-02-2015 Study

Sponsor: Quince Therapeutics S.p.A.

Interventions EryDex System
Updated 11 times since 2018 Last updated: Sep 12, 2024 Started: Jun 12, 2018 Primary completion: Sep 2, 2022 Completion: Sep 2, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

terminated by sponsor

Other terminated trials from Quince Therapeutics S.p.A.

More terminations from Quince Therapeutics S.p.A.

Other Ataxia Telangiectasia trials with similar outcome

Browse all Ataxia Telangiectasia trials

A PHASE3 clinical study on Ataxia Telangiectasia and Genetic Syndrome, this trial is terminated or withdrawn. The trial is conducted by Quince Therapeutics S.p.A. and has accumulated 11 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jul 2018 – ~Jan 2019 · 6 months · monthly snapshotNot Yet Recruiting~Jan 2019 – ~Jun 2019 · 5 months · monthly snapshotRecruiting~Jun 2019 – ~Feb 2020 · 8 months · monthly snapshotRecruiting~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshotRecruiting~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshotRecruiting~Sep 2021 – ~Sep 2023 · 24 months · monthly snapshotRecruiting~Sep 2023 – ~Jun 2024 · 9 months · monthly snapshotUnknown Status~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotRecruiting~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshotRecruiting~Nov 2024 – present · 20 months · monthly snapshotTerminated

Change History

11 versions recorded
  1. Nov 2024 — Present [monthly]

    Terminated PHASE3

    Status: RecruitingTerminated

  2. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

  4. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE3

    Status: Unknown StatusRecruiting

  5. Sep 2023 — Jun 2024 [monthly]

    Unknown Status PHASE3

    Status: RecruitingUnknown Status

Show 6 earlier versions
  1. Sep 2021 — Sep 2023 [monthly]

    Recruiting PHASE3

  2. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  3. Feb 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  4. Jun 2019 — Feb 2020 [monthly]

    Recruiting PHASE3

  5. Jan 2019 — Jun 2019 [monthly]

    Recruiting PHASE3

    Status: Not Yet RecruitingRecruiting

  6. Jul 2018 — Jan 2019 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Jun 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Quince Therapeutics S.p.A.
Data source: Quince Therapeutics S.p.A.

For direct contact, visit the study record on ClinicalTrials.gov .